Good to see author Chris Behrenbruch eating humble pie and admitting he was wrong
An extract taken from an article published earlier
I would love to invest in Starpharma (ASX : SPL) because I think their basic technology platform is interesting. Unfortunately they are currently pissing away millions of dollars of shareholder capital on a Phase III trial that probably isn’t going to work, and has the mediocre tendency to put out retail investor hype that has little nor no scientific merit
SPL Price at posting:
88.0¢ Sentiment: Buy Disclosure: Held
